Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is sirt1-independent

Drug Target Insights

Volumn 2012, Issue 6, 2012, Pages 1-11

  Annabi, Borhane ^a   Lord Dufour, Simon ^a   Vézina, Amélie ^a   Béliveau, Richard ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Angiogenesis; Brain endothelial cells; COX 2; Inflammation; MMP 9; Resveratrol; Sirt1

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CARCINOGEN; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; RESVERATROL; RNA; SIRTUIN 1;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN TUMOR; CANCER GRADING; CELL LYSATE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CULTURE MEDIUM; DIET; ENDOTHELIUM CELL; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME RELEASE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; INFLAMMATION; MICROARRAY ANALYSIS; NERVOUS SYSTEM INFLAMMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; ZYMOGRAPHY;

EID: 84860865702     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.S9442     Document Type: Article

References (48)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angio-genic switch during tumorigenesis. Cell. 1996;86:353-364.
2. Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis. 2010; 31:334-341.
3. Hayes A. Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory drugs-can we combine all three? Vet Comp Oncol. 2007;5:1-13.
4. Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429-434.
5. Fournier LS, Novikov V, Lucidi V, et al. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology. 2007;243:105-111.
6. Müller-Decker K, Fürstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog. 2007;46:705-710.
7. Neergheen VS, Bahorun T, Taylor EW, Jen LS, Aruoma OI. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology. 2010;278:229-241.
8. Lakka SS, Gondi CS, Rao JS. Proteases and glioma angiogenesis. Brain Pathol. 2005;15:327-341.
9. Bonoiu A, Mahajan SD, Ye L, et al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 2009;1282:142-155.
10. Annabi B, Rojas-Sutterlin S, Laroche M, Lachambre MP, Moumdjian R, Béliveau R. The diet-derived sulforaphane inhibits matrix metalloproteinase-9-activated human brain microvascular endothelial cell migration and tubulogenesis. Mol Nutr Food Res. 2008;52:692-700.
11. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Distinct patterns of matrix metalloproteinase-2 and -9 expression in normal human cell lines. Oncol Rep. 2009;21:821-826.
12. Jadhav U, Chigurupati S, Lakka SS, Mohanam S. Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol. 2004;25:1407-1414.
13. Luqman S, Pezzuto JM. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res. 2010;24:949-963.
14. Tergaonkar V. NFkappaB pathway: a good signaling paradigm and therapeutic target. Int J Biochem Cell Biol. 2006;38:1647-1653.
15. Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle. 2008;7:2117-2122.
16. Schlicker C, Boanca G, Lakshminarasimhan M, Steegborn C. Structure-based development of novel sirtuin inhibitors. Aging (Albany NY). 2011;3: 852-872.
17. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.
18. Chang CJ, Hsu CC, Yung MC, et al. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun. 2009;380:236-242.
19. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14:312-323.
20. Centeno-Baez C, Dallaire P, Marette A. Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am J Physiol Endocrinol Metab. 2011;301:E922-E930.
21. Tahanian E, Peiro S, Annabi B. Low intracellular ATP levels exacerbate carcinogen-induced inflammatory stress response and inhibit in vitro tubu-logenesis in human brain endothelial cells. J Infamm Res. 2011;4:1-10.
22. Greiffenberg L, Goebel W, Kim KS, et al. Interaction of Listeria monocy-togenes with human brain microvascular endothelial cells: InlB-dependent invasion, long-term intracellular growth, and spread from macrophages to endothelial cells. Infect Immun. 1998;66:5260-5267.
23. Sina A, Lord-Dufour S, Annabi B. Cell-based evidence for aminopeptidase N/CD13 inhibitor actinonin targeting of MT1-MMP-mediated proMMP-2 activation. Cancer Lett. 2009;279:171-176.
24. Abécassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res. 2003;291:363-376.
25. Annabi B, Currie JC, Moghrabi A, Béliveau R. Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk Res. 2007;31:1277-1284.
26. Tahanian E, Lord-Dufour S, Das A, Khosla C, Roy R, Annabi B. Inhibition of tubulogenesis and of carcinogen-mediated signaling in brain endothelial cells highlight the antiangiogenic properties of a mumbaistatin analog. Chem Biol Drug Des. 2010;75:481-488.
27. Annabi B, Vaillancourt-Jean E, Weil AG, Béliveau R. Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells. Onco Targets Ther. 2010;3: 219-226.
28. Dong J, Jimi E, Zeiss C, Hayden MS, Ghosh S. Constitutively active NF-kappaB triggers systemic TNFalpha-dependent infammation and localized TNFalpha-independent inflammatory disease. Genes Dev. 2010;24: 1709-1717.
29. Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signalling. Immunol Res. 2008;42:3-18.
30. Craggs L, Kalaria RN. Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport. 2011;22:1-3.
31. Boocock DJ, Patel KR, Faust GE, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:182-187.
32. Meng X, Maliakal P, Lu H, Lee MJ, Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem. 2004;52:935-942.
33. Bishayee A, Waghray A, Barnes KF, et al. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res. 2010;27:1080-1091.
34. Boily G, He XH, Pearce B, Jardine K, McBurney MW. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene. 2009;28:2882-9283.
35. Pfster JA, Ma C, Morrison BE, D'Mello SR. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One. 2008;3:e4090.
36. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425: 191-196.
37. Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev. 2008;6:591-596.
38. Anekonda TS. Resveratrol--a boon for treating Alzheimer's disease? Brain Res Rev. 2006;52:236-316.
39. van Acker SA, Tromp MN, Haenen GR, van der Vijgh WJ, Bast A. Flavonoids as scavengers of nitric oxide radical. Biochem Biophys Res Commun. 1995;214:755-759.
40. Laughton MJ, Evans PJ, Moroney MA, Hoult JR, Halliwell B. Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by favonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol. 1991;42:1673-1681.
41. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 2009;23:2810-2819.
42. Woo JH, Lim JH, Kim YH, et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene. 2004;23:1845-1853.
43. Gao Z, Ye J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun. 2008;376:793-796.
44. In: Rice-Evans C, Packer L, editors: Flavonoids in Health and Disease (second ed.), Marcel Dekker Inc, New York/Basel (2003).
45. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377-1382.
46. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 2002;302:369-373.
47. Abd El-Mohsen M, Bayele H, Kuhnle G, et al. Distribution of [3H]trans- resveratrol in rat tissues following oral administration. Br J Nutr. 2006;96: 62-70.
48. Yu C, Shin YG, Chow A, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res. 2002;19:1907-1914